KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $41.0 million.

  • Nektar Therapeutics' Cash & Equivalents rose 3627.82% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year increase of 3627.82%. This contributed to the annual value of $44.3 million for FY2024, which is 2544.15% up from last year.
  • As of Q3 2025, Nektar Therapeutics' Cash & Equivalents stood at $41.0 million, which was up 3627.82% from $43.0 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Cash & Equivalents high stood at $152.3 million for Q2 2021, and its period low was $25.2 million during Q4 2021.
  • Its 5-year average for Cash & Equivalents is $64.4 million, with a median of $50.7 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 8732.48% in 2021, then soared by 24985.72% in 2022.
  • Nektar Therapeutics' Cash & Equivalents (Quarter) stood at $25.2 million in 2021, then skyrocketed by 249.86% to $88.2 million in 2022, then crashed by 60.02% to $35.3 million in 2023, then rose by 25.44% to $44.3 million in 2024, then dropped by 7.28% to $41.0 million in 2025.
  • Its Cash & Equivalents was $41.0 million in Q3 2025, compared to $43.0 million in Q2 2025 and $38.9 million in Q1 2025.